Table 3 Clinical variables according to the presence or absence of anti-annexin V at baseline
From: Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study
Variable | Anti-annexin V IgG | p value | Anti-annexin V IgM | p value | ||
|---|---|---|---|---|---|---|
Positive (n = 11) | Negative (n = 59) | Positive (n = 10) | Negative (n = 60) | |||
Age (years), mean ± SD | 48.73 ± 11.30 | 46.42 ± 12.79 | 0.579 | 49.90 ± 15.55 | 46.27 ± 12.02 | 0.399 |
Gender (F/M), n (%) | 10/1 | 55/4 | 0.586 | 9/1 | 56/4 | 0.549 |
RP duration before diagnosis (years), mean ± SD | 3.09 ± 3.48 | 5.47 ± 6.48 | 0.241 | 3.80 ± 3.88 | 5.32 ± 6.45 | 0.475 |
Disease duration (years), mean ± SD | 9.18 ± 4.29 | 9.46 ± 6.59 | 0.894 | 10.00 ± 7.38 | 9.32 ± 6.12 | 0.752 |
Cutaneous subset (Diffuse/Limited) | 5/6 | 20/39 | 0.341 | 3/7 | 22/38 | 0.490 |
Modified Rodnan cutaneous score | 17.91 ± 13.05 | 12.22 ± 9.89 | 0.101 | 11.80 ± 9.77 | 13.33 ± 10.74 | 0.674 |
Calcinosis, n (%) | 3 (27.3) | 8 (13.6) | 0.232 | 2 (20.0) | 9 (15.0) | 0.493 |
Telangiectasia, n (%) | 5 (45.5) | 33 (55.9) | 0.261 | 6 (60.0) | 32 (53.3) | 0.655 |
Puffy fingers, (%) | 1 (9.1) | 12 (20.3) | 0.345 | 0 (0.0) | 13 (21.7) | 0.109 |
Active digital ulcers, n (%) | 3 (27.3) | 11 (18.6) | 0.382 | 1 (10.0) | 13 (21.7) | 0.357 |
Recurrent digital ulcers, n (%) | 4 (36.4) | 11 (18.6) | 0.177 | 1 (10.0) | 14 (23.3) | 0.314 |
Necrosis or amputation of extremities, n (%) | 3 (27.3) | 1 (1.7) | 0.011 | 1 (10.0) | 3 (5.0) | 0.232 |
Arthritis, n (%) | 4 (36.4) | 16 (27.1) | 0.385 | 3 (30.0) | 17 (28.3) | 0.591 |
Esophageal involvement, n (%) | 10 (90.9) | 43 (72.9) | 0.188 | 9 (90.0) | 44 (73.3) | 0.239 |
FVC < 70% predicted, n (%) | 6 (54.5) | 13 (22.0) | 0.036 | 3 (30.0) | 16 (26.7) | 0.548 |
Interstitial lung involvement on CT scan, n (%) | 8 (72.7) | 28 (47.5) | 0.112 | 7 (70.0) | 29 (48.3) | 0.177 |
PAH, n (%) | 3 (27.3) | 4 (6.8) | 0.048 | 3 (30.0) | 4 (6.7) | 0.036 |
Diastolic dysfunction, n (%) | 5 (45.5) | 12 (20.3) | 0.085 | 3 (30.0) | 14 (23.3) | 0.457 |
Renal crisis, n (%) | 0 (0.0) | 3 (5.1) | 0.594 | 0 (0.0) | 3 (5.0) | 0.625 |
Raynaud Condition Score | 6.00 ± 2.12 | 5.07 ± 2.27 | 0.002 | 5.18 ± 2.44 | 5.09 ± 2.29 | 0.873 |
HAQ-DI (score 0–3) | 1.17 ± 0.55 | 0.70 ± 0.49 | 0.006 | 0.73 ± 0.58 | 0.78 ± 0.52 | 0.777 |
ACA, n (%) | 5 (45.5) | 23 (38.9) | 0.688 | 6 (60.0) | 22 (36.7) | 0.163 |
Anti-Scl-70, n (%) | 5 (45.5) | 16 (27.1) | 0.223 | 3 (30.0) | 18 (30.0) | 1.000 |
Anti-RNA polymerase III, n (%) | 0 (0.0) | 5 (8.5) | 0.316 | 0 (0.0) | 5 (8.3) | 0.343 |
Nailfold videocapillaroscopy | ||||||
 Number of capillaries/mm | 7.14 ± 1.03 | 7.35 ± 1.00 | 0.513 | 7.09 ± 0.89 | 7.36 ± 1.02 | 0.429 |
 Enlarged capillaries | 1.40 ± 0.73 | 1.0 ± 0.79 | 0.198 | 1.32 ± 0.57 | 1.08 ± 0.82 | 0.367 |
 Giant capillaries | 0.24 ± 0.23 | 0.21 ± 0.24 | 0.728 | 0.29 ± 0.21 | 0.21 ± 0.24 | 0.313 |
 Microhemorrhages | 0.56 ± 0.46 | 0.66 ± 0.63 | 0.624 | 1.0 ± 0.93 | 0.58 ± 0.51 | 0.192 |
 Avascular score | 1.16 ± 0.59 | 0.93 ± 0.74 | 0.330 | 1.23 ± 0.66 | 0.92 ± 0.72 | 0.218 |